Patrick Nachman, MD
Nephrology · Minneapolis, MNNPI 1912075144
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,110 of the $7,260 with a category attached, or 84.2%. 9 manufacturers reported payments, led by GSK at 57.3% of the total. Reporting peaked in 2023 at $3,963 and has fallen 90.5% since, to $376 in 2025. Among nephrology clinicians in MN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 11 payments — averaging $660.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$4K
- Novartis$2K
- Sanofi$671
- Apellis Pharmaceuticals, Inc.$139
- Calliditas Therapeutics US Inc.$118
- AstraZeneca$99
- plus $124 from 3 others
Across 4 payments — averaging $26,802 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$77K
- Sanofi$28K
- Novartis$2K
What the payments were for
- Consulting fees$6,11084%
- Grants$6719%
- Food & beverage$4186%
- Education$611%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 3 | $4,160 |
| Novartis | 1 | $1,950 |
| Sanofi | 1 | $671 |
| Apellis Pharmaceuticals, Inc. | 1 | $139 |
| Calliditas Therapeutics US Inc. | 1 | $118 |
| AstraZeneca | 1 | $99 |
| Otsuka America Pharmaceutical, Inc. | 1 | $61 |
| Vertex | 1 | $42 |
| Boehringer Ingelheim International GmbH | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,260 in reported general payments places this provider in the 90th percentile of 208 nephrology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mycophenolate Mofetil | 12 | $492 |
| Losartan Potassium | 23 | $279 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 14 | $241 |
| Lisinopril | 12 | $213 |
| Furosemide | 17 | $176 |
| Amlodipine Besylate | 15 | $165 |
| Carvedilol | 12 | $126 |
| Atorvastatin Calcium | 12 | $96 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Minneapolis
- Kirsten JohansenMinneapolis$101K
- Jeffrey KohenMinneapolis$56K
- James WetmoreMinneapolis$48K
- Robert FoleyMinneapolis$12K
- Jeffrey ConnaireMinneapolis$11K
- Charles SmithMinneapolis$4K
- Mirna BoumitriMinneapolis$3K
- Jiwan ThapaMinneapolis$3K
- Suzanne SwanMinneapolis$2K
- Arda AkolukMinneapolis$777
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.